Why in news?
Spinal Muscular Atrophy (SMA) frequently appears in medical news and civil services examinations due to its genetic nature and recent advances in treatment. Understanding its cause, types and management is important for UPSC aspirants.
Background
SMA is a group of inherited neuromuscular disorders that cause progressive muscle weakness and wasting. The condition results from mutations in the SMN1 (Survival Motor Neuron 1) gene on chromosome 5. This gene produces the SMN protein, vital for the survival of motor neurons—the nerve cells that control voluntary muscles. When the body cannot produce enough SMN protein, motor neurons degenerate, leading to muscle atrophy.
The number of copies of a related gene, SMN2, influences disease severity. SMA is inherited in an autosomal recessive manner, meaning both parents must pass on a mutated SMN1 allele for a child to be affected. Carriers typically show no symptoms.
Types of SMA
- Type 0 (congenital): A rare and severe form affecting infants before birth. Babies show decreased movement in utero and severe weakness at birth. Survival beyond a few weeks is uncommon.
- Type 1 (Werdnig–Hoffmann disease): Symptoms appear within the first six months of life. Infants have poor head control, difficulty swallowing and breathing problems. Without respiratory support, many do not survive beyond two years.
- Type 2 (Dubowitz disease): Onset between six and 18 months. Children can sit but generally cannot walk. Muscle weakness mainly affects the legs. Respiratory complications are a major cause of mortality.
- Type 3 (Kugelberg–Welander disease): Appears after 18 months, sometimes in adolescence. People can walk but may lose mobility later. Life expectancy is near normal.
- Type 4 (adult onset): The mildest form, beginning after age 21. It causes gradual leg weakness but rarely affects lifespan.
Symptoms and diagnosis
- Common symptoms: Weakness of proximal muscles (shoulders, hips, thighs), poor reflexes, difficulty swallowing and respiratory problems. Severity depends on the type.
- Diagnosis: Genetic testing confirms mutations in SMN1. Newborn screening programmes detect SMA early. Additional tests such as electromyography and muscle biopsy may support the diagnosis.
Management
- There is currently no cure. Management focuses on supportive care—physiotherapy, occupational therapy and respiratory assistance.
- Assistive devices such as braces, wheelchairs and ventilators improve quality of life.
- Research into gene therapies and SMN‑enhancing drugs offers hope for modifying disease progression.
Significance
SMA is one of the most common inherited causes of infant mortality after cystic fibrosis. Awareness aids early diagnosis and access to supportive interventions. Advances in genetic medicine may provide targeted treatments in the future.
